Dacomitinib was highly effective at blocking EGFR phosphorylation in all three SCCHN cell lines, resulting in decreased proliferation, reduced clonogenicity, along with a significant increase in G1 cell cycle arrest in vitro. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.